Viridian Therapeutics

Waltham, US · Founded 2020 · Delaware corporation · 3 known investors

Viridian Therapeutics develops treatments for thyroid eye disease, a rare autoimmune condition affecting the eyes and orbit. The company focuses on clinical development and patient support programs in the biotech sector.

BiotechDigital HealthMedical Devicesin /viridiantx @viridianthera

Founders & leadership

Jonathan ViolinExecutive Officer, Director

Peter HarwinDirector

Tomas KiselakDirector

Investors · 3

Broadview VenturesBoston

Longitude CapitalMenlo Park · $10M – $30M

MRL Ventures FundCambridge · $25M

Reported raises · per SEC filings

Form D private placements

▶$27MraisedSep 2020 · 9 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Jonathan ViolinExecutive Officer, Director
Tomas KiselakDirector
Peter HarwinDirector

Offering amount: $27M
Amount sold: $27M
First sale: Sep 2020
Incorporated: Corporation, Delaware, 2020
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$2MraisedMay 2020 · 2 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Jonathan ViolinExecutive Officer, Director
Peter HarwinDirector
Tomas KiselakDirector

Offering amount: $5M
Amount sold: $2M
First sale: Apr 2020
Incorporated: Corporation, Delaware, 2020
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.